Market News & Trends
Roquette Earns USDA Certified Biobased Product Label for BIOSUCCINIUM
Roquette recently announced it has earned the US Department of Agriculture (USDA) Certified Biobased Product label. The product, BIOSUCCINIUM® succinic acid, is now able to…
Nemera & BIOMM Sign Partnership Agreement to Commercialize Reusable Insulin Pen in Brazil
A pioneer in biotechnological medicines in Brazil, BIOMM is launching Nemera’s Advapen under the trade name Lifepen® for the administration of….
Evaxion Biotech Reports Data From Phase 1/2a Trials of EVX-01 & EVX-02
Evaxion Biotech A/S recently announced results from both its Phase 1/2a trial of cancer immunotherapy EVX-01 in metastatic melanoma and interim Phase 1/2a trial of…
Ensysce Biosciences Receives Notice of Award for Year 3 of Multi-Year NIDA Grant for the Clinical Development of its Next-Generation Opioid Products With Overdose Protection
Ensysce Biosciences, Inc. recently announced receipt of the third year award of a multi-year grant from the National Institute on Drug Abuse (NIDA). This award…
Valneva Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vaccine Candidate
Valneva SE recently announced it has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553, by the US FDA. Breakthrough Therapy Designation…
Akston Biosciences Announces Positive Phase 1 Data for Second-Generation COVID-19 Vaccine Candidate
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, recently announced positive results from a 60-subject, open-label, Phase 1 trial of AKS-452, its…
LGM Pharma Launches New Stand-Alone Analytical Services Offering for Drug Developers & Manufacturers
LGM Pharma, a long-time leader in API sourcing, completed a transformational acquisition last year of long-established CDMO NexGen Pharma. Among the many new capabilities LGM…
Recipharm Signs Memorandum of Understanding (MOU) for the Fill Finish of Vaccines & Biotherapeutics in Morocco
Global contract development and manufacturing organization (CDMO) Recipharm has recently signed an MOU, along with His Majesty the King of Morocco, Mohammed VI, the Moroccan Government and….
Brickell Biotech Announces Final Patient Completed in First US Phase 3 Pivotal Clinical Study & Patient Enrollment Completed in Second US Phase 3 Pivotal Clinical Study
Brickell Biotech, Inc. recently announced the final patient has completed the Phase 3 pivotal Cardigan I study, and that all planned patients have been enrolled in the Phase 3 pivotal Cardigan II study…..
BioAegis Awarded BARDA Contract to Advance Development of a Novel Host-Directed Human Protein for Patients With Sepsis & Severe Infection
BioAegis Therapeutics Inc. recently announced it was awarded a contract from Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services, to further….
Apellis & Beam Therapeutics Enter Exclusive Research Collaboration
Apellis Pharmaceuticals, Inc. and Beam Therapeutics Inc. recently announced an exclusive 5-year research collaboration focused on the use of Beam’s proprietary base editing technology to discover new….
Encoded Therapeutics Partners With Genedata to Accelerate AAV-Based Gene Therapy Development
Genedata recently announced that Encoded Therapeutics has chosen Genedata Bioprocess to digitalize their proprietary gene therapy R&D technology…..
Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative & Biothreat Pathogens
Entasis Therapeutics Holdings Inc. recently announced the presentation of preclinical data on ETX0462, a novel, first-in-class, diazabicyclooctane with antimicrobial activity against multidrug-resistant (MDR) Gram-negative and…
Atea’s Oral Antiviral Drug Candidate Reduces Viral Replication in Hospitalized Patients With COVID-19 in Phase 2 Interim Analysis
Atea Pharmaceuticals, Inc. recently announced positive interim results from the global Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-moderate COVID-19. Roche and Atea…
Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients With Chronic Rhinosinusitis
Lyra Therapeutics, Inc. recently announced positive topline results from the company’s pharmacokinetic (PK) study of LYR-210. Data obtained from the study are supportive of LYR-210’s…
Halberd Corp. Discovers a Proprietary Disease-Causing Antigen Removal Process Method Does Not Require Antibody Conjugated Metallic Nanoparticles
Halberd Corporation recently announced a possible breakthrough method for the removal of the disease-causing antigen(s) that does not require the use of metallic nanoparticles conjugated…
OSE Immunotherapeutics Announces Manufacturing Agreement With Cenexi
OSE Immunotherapeutics and Cenexi recently announced the signature of an agreement whereby Cenexi will manufacture clinical batches of CoVepiT, OSE Immunotherapeutics' vaccine candidate against COVID-19 currently…
Altimmune Announces Update on AdCOVID Phase 1 Clinical Trial
Altimmune, Inc. recently provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19. The company also provided an update on its T-COVID…
Evonik Markets Novel Chemical Technology for More Sustainable Pharmaceutical Production
Evonik offers an innovative green technology that enables the large-scale synthesis of active pharmaceutical ingredients in water. The “Chemistry in Water” technology has the potential….
LEXEO Therapeutics Receives Rare Pediatric Disease Designation & Orphan Drug Designation
LEXEO Therapeutics recently announced the US FDA has granted Rare Pediatric Disease designation and Orphan Drug designation to LX2006 for the treatment of….
